Novel immunotherapeutic to be produced in CMC Biologics’ microbial facility in Copenhagen
CMC Biologics, Inc., a global leader in clinical and commercial manufacturing of therapeutic proteins, today announced that they have entered into an agreement with Immunocore Limited, a leading UK-based biotechnology company focused on developing new treatments for cancer, viral infections and autoimmune diseases, for the process transfer and cGMP production of IMCgp100, Immunocore’s lead product. IMCgp100 is a novel first-in-class cancer immunotherapeutic based on proprietary platform T- cell receptor (TCR) technology.
Under the agreement, CMC Biologics will transfer and scale up Immunocore’s manufacturing process for IMCgp100 in its world class microbial facility in Copenhagen, Denmark for cGMP manufacture to support Immunocore’s pivotal clinical trials globally.
“We are delighted to be working with Immunocore, one of the fastest growing and innovative biotech companies in Europe,” said Gustavo Mahler, PhD, Global Chief Operations Officer of CMC Biologics. “We aim to support Immunocore in their drive to achieve early approval of IMCgp100 through our continued focus on manufacturing excellence and customer service.”
“We selected CMC Biologics as our manufacturing partner for IMCgp100 because of their ability to support our accelerated program for planned commercialization of IMCgp100. They have strong development capabilities with commercial cGMP facilities,” said Eva-Lotta Allan, Chief Business Officer of Immunocore Limited. “The successful transfer and production of IMCgp100 is critical to meeting our aggressive clinical and commercial manufacturing timelines.”